治疗成人重症肌无力新药zilucoplan的药理作用与临床评价
Pharmacological effects and clinical evaluation of zilucoplan for generalized myasthenia gravis
程璐 1解染 1赵楠 1贾博 1赵侠1
作者信息
- 1. 北京大学第一医院药物临床试验机构,北京 100009
- 折叠
摘要
Zilucoplan是一种自行皮下给药的大环肽类补体C5新型抑制药,2023年10月被FDA批准上市,用于治疗抗乙酰胆碱受体(AChR)抗体阳性的全身型重症肌无力(gMG)成年患者.本文就zilucoplan的药理作用、药代动力学、临床研究及安全性等进行介绍.
Abstract
Zilucoplan is a novel subcutaneous self-administered macrocyclic peptide inhibitor of complement component 5.It was approved by the FDA in October 2023 for the treatment of adults with generalized myasthenia gravis(gMG)who are positive for acetylcholine receptor(AChR)antibodies.This article reviews its pharmacological action,pharmacokinetics,clinical evaluation and safety.
关键词
zilucoplan/补体C5抑制剂/重症肌无力/临床评价/安全性Key words
zilucoplan/inhibitor of complement component 5/generalized myasthenia gravis/clinical evaluation/safety引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据